Objective To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90% CI 0.79 to 0.98) and 0.81 (90% CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90% CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90% CI 0.81 to 0.98). Conclusions Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.

Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study / Schneider, R.; Mckeever, P.; Kim, T.; Graff, C.; Van Swieten, J. C.; Karydas, A.; Boxer, A.; Rosen, H.; Miller, B. L.; Laforce, R.; Galimberti, D.; Masellis, M.; Borroni, B.; Zhang, Z.; Zinman, L.; Rohrer, J. D.; Tartaglia, M. C.; Robertson, J.; Andersson, C.; Archetti, S.; Arighi, A.; Benussi, L.; Binetti, G.; Black, S.; Bocchetta, M.; Cash, D.; Cosseddu, M.; Dick, K.; Fallström, M.; Ferreira, C.; Fenoglio, C.; Fox, N.; Freedman, M.; Frisoni, G.; Fumagalli, G.; Gazzina, S.; Ghidoni, R.; Grisoli, M.; Jelic, V.; Jiskoot, L.; Keren, R.; Lombardi, G.; Maruta, C.; Meeter, L.; van Minkelen, M.; Nacmias, B.; Öijerstedt, L.; Ourselin, S.; Padovani, A.; Panman, J.; Pievani, M.; Polito, C.; Premi, E.; Prioni, S.; Rademakers, R. Redaelli V.; Rogaeva, E.; Rossi, G.; Rossor, M.; Row, J.; Scarpini, E.; Tagliavini, F.; Sorbi, S.; Tang-Wai, D.; Thomas, D.; Thonberg, H.; Tiraboschi, P.; Verdelho, A.; Warren, J.. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - 89:8(2018), pp. 851-858. [10.1136/jnnp-2017-317492]

Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study

Fumagalli G.;
2018-01-01

Abstract

Objective To determine whether exosomal microRNAs (miRNAs) in cerebrospinal fluid (CSF) of patients with frontotemporal dementia (FTD) can serve as diagnostic biomarkers, we assessed miRNA expression in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort and in sporadic FTD. Methods GENFI participants were either carriers of a pathogenic mutation in progranulin, chromosome 9 open reading frame 72 or microtubule-associated protein tau or were at risk of carrying a mutation because a first-degree relative was a known symptomatic mutation carrier. Exosomes were isolated from CSF of 23 presymptomatic and 15 symptomatic mutation carriers and 11 healthy non-mutation carriers. Expression of 752 miRNAs was measured using quantitative PCR (qPCR) arrays and validated by qPCR using individual primers. MiRNAs found differentially expressed in symptomatic compared with presymptomatic mutation carriers were further evaluated in a cohort of 17 patients with sporadic FTD, 13 patients with sporadic Alzheimer's disease (AD) and 10 healthy controls (HCs) of similar age. Results In the GENFI cohort, miR-204-5p and miR-632 were significantly decreased in symptomatic compared with presymptomatic mutation carriers. Decrease of miR-204-5p and miR-632 revealed receiver operator characteristics with an area of 0.89 (90% CI 0.79 to 0.98) and 0.81 (90% CI 0.68 to 0.93), respectively, and when combined an area of 0.93 (90% CI 0.87 to 0.99). In sporadic FTD, only miR-632 was significantly decreased compared with AD and HCs. Decrease of miR-632 revealed an area of 0.90 (90% CI 0.81 to 0.98). Conclusions Exosomal miR-204-5p and miR-632 have potential as diagnostic biomarkers for genetic FTD and miR-632 also for sporadic FTD.
2018
8
Schneider, R.; Mckeever, P.; Kim, T.; Graff, C.; Van Swieten, J. C.; Karydas, A.; Boxer, A.; Rosen, H.; Miller, B. L.; Laforce, R.; Galimberti, D.; Masellis, M.; Borroni, B.; Zhang, Z.; Zinman, L.; Rohrer, J. D.; Tartaglia, M. C.; Robertson, J.; Andersson, C.; Archetti, S.; Arighi, A.; Benussi, L.; Binetti, G.; Black, S.; Bocchetta, M.; Cash, D.; Cosseddu, M.; Dick, K.; Fallström, M.; Ferreira, C.; Fenoglio, C.; Fox, N.; Freedman, M.; Frisoni, G.; Fumagalli, G.; Gazzina, S.; Ghidoni, R.; Grisoli, M.; Jelic, V.; Jiskoot, L.; Keren, R.; Lombardi, G.; Maruta, C.; Meeter, L.; van Minkelen, M.; Nacmias, B.; Öijerstedt, L.; Ourselin, S.; Padovani, A.; Panman, J.; Pievani, M.; Polito, C.; Premi, E.; Prioni, S.; Rademakers, R. Redaelli V.; Rogaeva, E.; Rossi, G.; Rossor, M.; Row, J.; Scarpini, E.; Tagliavini, F.; Sorbi, S.; Tang-Wai, D.; Thomas, D.; Thonberg, H.; Tiraboschi, P.; Verdelho, A.; Warren, J.
Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: A GENFI study / Schneider, R.; Mckeever, P.; Kim, T.; Graff, C.; Van Swieten, J. C.; Karydas, A.; Boxer, A.; Rosen, H.; Miller, B. L.; Laforce, R.; Galimberti, D.; Masellis, M.; Borroni, B.; Zhang, Z.; Zinman, L.; Rohrer, J. D.; Tartaglia, M. C.; Robertson, J.; Andersson, C.; Archetti, S.; Arighi, A.; Benussi, L.; Binetti, G.; Black, S.; Bocchetta, M.; Cash, D.; Cosseddu, M.; Dick, K.; Fallström, M.; Ferreira, C.; Fenoglio, C.; Fox, N.; Freedman, M.; Frisoni, G.; Fumagalli, G.; Gazzina, S.; Ghidoni, R.; Grisoli, M.; Jelic, V.; Jiskoot, L.; Keren, R.; Lombardi, G.; Maruta, C.; Meeter, L.; van Minkelen, M.; Nacmias, B.; Öijerstedt, L.; Ourselin, S.; Padovani, A.; Panman, J.; Pievani, M.; Polito, C.; Premi, E.; Prioni, S.; Rademakers, R. Redaelli V.; Rogaeva, E.; Rossi, G.; Rossor, M.; Row, J.; Scarpini, E.; Tagliavini, F.; Sorbi, S.; Tang-Wai, D.; Thomas, D.; Thonberg, H.; Tiraboschi, P.; Verdelho, A.; Warren, J.. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - 89:8(2018), pp. 851-858. [10.1136/jnnp-2017-317492]
File in questo prodotto:
File Dimensione Formato  
2018 Schneider et al.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/355944
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact